조직학 및 세포학 시장 : 시험 유형별, 제품별, 검사 유형별, 용도별, 최종사용자별 - 세계 기회 분석과 산업 예측(2023-2032년)

Histology and Cytology Market By Type of Examination, By Product, By Test Type, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

US $ 5,730 ￦ 8,200,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 9,600 ￦ 13,739,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

세계의 조직학·세포학 시장은 2022년에 72억 달러에 달하며, 2023-2032년에 11.9%의 CAGR로 성장하며, 2032년까지는 222억 달러에 달할 것으로 예측되고 있습니다.

조직학 및 세포학은 헬스케어 분야에서 필수적인 분석 기술이며, 다양한 질환의 진단 및 치료 관리에 있으며, 매우 중요한 의미를 지닙니다. 조직학은 조직의 현미경 검사를 통해 조직의 구조적 특징을 정밀하게 조사하고 이상을 확인합니다. 반면, 세포학은 개별 세포의 검사에 집중하여 이상이나 질병을 식별합니다. 이러한 진단 방법은 암, 감염 및 기타 병적 상태를 적시에 식별하는 데 중요한 역할을 합니다.

암과 같은 만성질환의 유병률 증가와 의료 인프라의 개선은 조직검사 및 세포검사 시장의 성장을 가속할 것으로 예상됩니다. 예를 들어 미국 암협회에 따르면 2020년 전 세계에서 약 1,930만 명의 신규 암 환자(비흑색종 피부암을 제외한 1,810만 명)와 약 1,000만 명의 암 사망자(비흑색종 피부암을 제외한 990만 명)가 발생할 것으로 예상된다고 보고했습니다. 암, 심혈관질환, 호흡기질환 등 만성질환의 현저한 증가로 인해 첨단 진단법과 스크리닝 방법이 절실히 요구되고 있습니다.

조직학 및 세포학 검사는 악성 종양과 관련된 세포 및 조직 수준의 변화에 대한 귀중한 인사이트을 제공하여 정확한 진단과 맞춤형 치료 전략을 수립하는 데 도움이 됩니다. 또한 전 세계에서 고령화가 진행됨에 따라 만성질환의 발생률이 증가함에 따라 질병 진단을 위한 조직 및 세포 검사에 대한 수요가 더욱 증가하고 있습니다.

또한 의료 전문가와 환자들의 인식이 높아지면서 조직학 및 세포학 검사에 대한 수요를 촉진하는 데 중요한 역할을 하고 있습니다. 환자들은 암과 감염성 질환을 포함한 다양한 질병을 진단하는 데 있으며, 조직 및 세포 검사의 중요성을 점점 더 많이 인식하고 있으며, 이는 이러한 진단 기술에 대한 수요 증가로 이어지고 있습니다. 또한 의료 전문가들도 정확하고 시기적절한 진단을 제공하는 조직 및 세포 진단의 이점을 더 많이 인식하고 있습니다. 의학 연구와 기술의 발전으로 의료 전문가들은 이러한 진단 툴의 중요성을 이해하고 임상 진료에 도입할 수 있게 되었습니다. 이러한 의료 전문가와 환자들의 인식이 높아짐에 따라 시장 성장을 가속할 것으로 예상됩니다.

또한 신흥 국가의 의료 인프라 개선도 시장 성장을 가속할 것으로 예상됩니다. 신흥 국가들은 의료 시스템 개선을 위한 투자로 인해 조직학, 세포학 등 질병 발견 및 관리에 중요한 역할을 하는 첨단 진단 기술에 대한 수요가 급증하고 있습니다. 예를 들어 국립의학도서관의 2023년 보고서에 따르면 2022 회계연도 기준 인도에는 2,000개 이상의 공공 의료시설이 있는 것으로 보고되었습니다. 병원, 진단 실험실, 연구센터 등 의료 시설의 확장과 현대화는 최첨단 조직학 및 세포학 기술을 채택할 수 있는 탄탄한 생태계를 구축하고 있습니다. 이러한 의료 인프라의 개선은 시장 성장에 크게 기여할 것으로 예상됩니다.

조직학 및 세포학 시장은 검사 유형, 제품, 검사 유형, 용도, 최종사용자, 지역별로 구분됩니다. 검사 유형에 따라 시장은 조직학 및 세포학으로 구분됩니다. 제품별로 시장은 기기 및 분석 소프트웨어 시스템, 소모품 및 시약으로 분류됩니다. 검사 유형에 따라 시장은 현미경 검사, 유세포 분석법, 분자 유전학적 방법으로 나뉩니다.

이해관계자 주요 이점

• 이 보고서는 2022-2032년 조직학 및 세포학 시장 분석 시장 부문, 현재 동향, 추정 동향 및 역학을 정량적으로 분석하여 조직학 및 세포학 시장의 유력한 시장 기회를 식별합니다.
• 시장 성장 촉진요인, 시장 성장 억제요인, 시장 기회와 관련된 정보와 함께 시장 조사를 제공합니다.
• Porter's Five Forces 분석은 이해 관계자가 이익 중심의 비즈니스 결정을 내리고 공급자와 구매자의 네트워크를 강화할 수 있도록 구매자와 공급자의 잠재력을 밝힙니다.
• 조직학 및 세포학 시장의 세분화를 자세히 분석하여 시장 기회를 파악할 수 있습니다.
• 각 지역의 주요 국가는 세계 시장에 대한 매출 기여도에 따라 매핑되어 있습니다.
• 시장 기업의 포지셔닝은 벤치마킹을 용이하게 하고 시장 기업의 현재 위치를 명확하게 이해할 수 있습니다.
• 이 보고서에는 지역별 및 세계 조직학 및 세포학 시장 동향, 주요 기업, 시장 부문, 용도, 시장 성장 전략에 대한 분석이 포함되어 있습니다.

기타 혜택은 다음과 같습니다.

• 분기별 최신 정보(기업 라이선스로만 이용 가능)
• 구매 전 또는 구매 후 원하는 기업 개요 5곳을 추가로 무료로 업데이트할 수 있습니다.
• 5개 사용자 라이선스 및 기업 사용자 라이선스 구매시 차기 버전 무료 제공.
• 분석가 16시간 지원(구매 후 보고서 검토를 통해 추가 데이터 요구사항이 발견될 경우, 질문 및 판매 후 문의사항 해결을 위해 16시간 동안 분석가의 지원을 받을 수 있음)
• 15% 무료 커스터마이징(보고서의 조사 범위 또는 부문이 고객의 요구 사항과 일치하지 않는 경우 15%는 3 영업일 무료 작업에 해당합니다.)
• 5개 사용자 라이선스 및 기업 사용자 라이선스 무료 데이터팩.(엑셀 버전 보고서)
• 6개월에서 12개월 이상 지난 보고서의 경우, 업데이트된 보고서를 무료로 제공합니다.
• 24시간 우선 대응
• 업계의 최신 정보와 백서를 무료로 제공합니다.
  
• 보고서 커스터마이징 가능(추가 비용과 타임라인에 관해서는 판매 담당에게 문의해주시기 바랍니다.)
• 고객의 관심사에 따른 기업 개요 추가
• 기업 개요 확장 리스트
• 과거 시장 데이터

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장의 정의와 범위
• 주요 조사 결과
  • 주요 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 촉진요인
    • 아시아태평양에서 제약 산업의 성장
    • 만성질환의 급증
    • 헬스케어 인프라의 개선
  • 억제요인
    • 조직학적·세포학적 분석 기기의 고비용
  • 기회
    • 조직학적·세포학적 분석 기술의 기술적 진보

제4장 조직학·세포학 시장 : 시험 유형별

• 개요
• 조직학
• 세포학

제5장 조직학·세포학 시장 : 제품별

• 개요
• 기기·분석 소프트웨어 시스템
• 소모품과 시약

제6장 조직학·세포학 시장 : 검사 유형별

• 개요
• 현미경검사법
• 유세포분석법
• 분자유전학적 검사법

제7장 조직학·세포학 시장 : 용도별

• 개요
• Drug Discovery·약제 설계
• 임상 진단
• 학술연구

제8장 조직학·세포학 시장 : 최종사용자별

• 개요
• 제약기업·바이오테크놀러지 기업
• CDMO
• 진단 연구소
• 기타

제9장 조직학·세포학 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타 유럽
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타 아시아태평양
• 라틴아메리카
  • 브라질
  • 콜롬비아
  • 아르헨티나
  • 기타 라틴아메리카
• 중동 및 아프리카
  • GCC
  • 남아프리카공화국
  • 북아프리카
  • 기타 중동 및 아프리카

제10장 경쟁 구도

• 서론
• 주요 성공 전략
• 주요 10사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝, 2022년

제11장 기업 개요

• Hologic, Inc.
• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Becton, Dickinson, and Company
• Danaher Corporation
• Merck KGaA
• Thermo Fisher Scientific, Inc.
• Sysmex Corporation
• Trivitron Healthcare Private Limited
• Koninklijke Philips N.V.

KSA

영문 목차

영문목차

The global histology and cytology market was valued at $7.2 billion in 2022, and is projected to reach $22.2 billion by 2032, growing at a CAGR of 11.9% from 2023 to 2032.

Histology and cytology constitute indispensable analytical techniques in the healthcare sector, holding a pivotal significance in the diagnosis and therapeutic management of diverse medical conditions. Histology entails the microscopic examination of tissues, scrutinizing their structural characteristics and identifying anomalies, whereas cytology concentrates on the examination of individual cells to identify abnormalities or diseases. These diagnostic methodologies play a critical role in the timely identification of cancer, infectious diseases, and other pathological conditions.

The rise in prevalence of chronic diseases such as cancer and the improving healthcare infrastructure is expected to drive the growth of the histology and cytology market. For instance, according to the American Cancer Society, it was reported that in 2020, Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. The notable increase in chronic conditions, such as cancer, cardiovascular diseases, and respiratory disorders, has created a pressing need for advanced diagnostic and screening methods.

Histology and cytology procedures provide invaluable insights into the cellular and tissue-level changes associated with malignancies, aiding in accurate diagnosis and the formulation of personalized treatment strategies. Moreover, as the aging population continues to grow worldwide, there is an inherent increase in the incidence of chronic diseases, further driving the demand for histology and cytology for disease diagnosis.

In addition, surge in awareness among healthcare professionals and patients plays a crucial role in driving the demand for histological and cytological examinations, as individuals become more proactive in managing their health and seeking early detection of diseases. Patients increasingly recognize the importance of histology and cytology in diagnosing various medical conditions, including cancers and infectious diseases, which has led to a rising demand for these diagnostic technologies. Moreover, healthcare professionals have become more aware of the benefits of histology and cytology in providing accurate and timely diagnoses. With advancements in medical research and technology, healthcare professionals are better equipped to understand the significance of these diagnostic tools and incorporate them into their clinical practices. Thus, the rise in awareness among the healthcare professionals and patients is expected to drive the growth of the market.

Furthermore, the improving healthcare infrastructure in developing countries is expected to drive the growth of the market. As countries across the developing regions progressively invest in upgrading their healthcare systems, there is a surge in demand for advanced diagnostic techniques, such as histology and cytology, which play a crucial role in disease detection and management. For instance, according to the 2023 report by National Library of Medicine, it was reported that over two lakh public health facilities were reported in India as of the financial year 2022. The expansion and modernization of healthcare facilities, including hospitals, diagnostic laboratories, and research centers, are creating a robust ecosystem for the adoption of cutting-edge histology and cytology technologies. Thus, the improving healthcare infrastructure is expected to significantly contribute to the growth of the market.

The histology and cytology market is segmented on the basis of type of examination, product, test type, application, end user, and region. On the basis of type of examination, the market is bifurcated into histology and cytology. On the basis of product, the market is classified into instruments and analysis software system and consumable and reagents. On the basis of test type, the market is divided into microscopy methods, flow cytometry, and molecular genetic methods.

On the basis of application, the market is segregated into drug discovery and designing, clinical diagnostics, and academic research. On the basis of end user, the market is fragmented into pharma & biotech companies, CDMO, diagnostic laboratories, and others. Others include hospital and academic research. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Major key players that operate in the histology and cytology market are Hologic, Inc., F. Hoffmann-La Roche Ltd., Abbott Laboratories, Becton, Dickinson and Company, Danaher Corporation, Merck KGaA, Thermo Fisher Scientific, Inc., Sysmex Corporation, Trivitron Healthcare Private Limited, and Koninklijke Philips N.V.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the histology and cytology market analysis from 2022 to 2032 to identify the prevailing histology and cytology market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the histology and cytology market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global histology and cytology market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.
  
• Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
• Additional company profiles with specific to client's interest
• Expanded list for Company Profiles
• Historic market data

Key Market Segments

By Type of Examination

• Histology
• Cytology

By Product

• Instruments and Analysis Software System
• Consumable and Reagents

By Test Type

• Microscopy Methods
• Flow Cytometry
• Molecular Genetic Methods

By Application

• Drug Discovery and Designing
• Clinical Diagnostics
• Academic Research

By End User

• Pharma and Biotech Companies
• CDMO
• Diagnostic Laboratories
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Colombia
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Gcc
  • South Africa
  • North Africa
  • Rest Of Mea

Key Market Players:

• Abbott Laboratories
• Merck KGaA
• Thermo Fisher Scientific, Inc.
• Trivitron Healthcare Private Limited
• Koninklijke Philips N.V.
• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Sysmex Corporation
• Becton, Dickinson, and Company
• Hologic, Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Low bargaining power of suppliers
  • 3.3.2. Low threat of new entrants
  • 3.3.3. Low threat of substitutes
  • 3.3.4. Low intensity of rivalry
  • 3.3.5. Low bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Growing Pharmaceutical Industry in Asia Pacific Region.
    • 3.4.1.2. Surge in prevalence of chronic diseases.
    • 3.4.1.3. Improving Healthcare Infrastructure.
  • 3.4.2. Restraints
    • 3.4.2.1. High cost of histological and cytological analytical instruments.
  • 3.4.3. Opportunities
    • 3.4.3.1. Technological advancement in the histological and cytological analysis technology.

CHAPTER 4: HISTOLOGY AND CYTOLOGY MARKET, BY TYPE OF EXAMINATION

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Histology
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Cytology
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country

CHAPTER 5: HISTOLOGY AND CYTOLOGY MARKET, BY PRODUCT

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Instruments and Analysis Software System
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Consumable and Reagents
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country

CHAPTER 6: HISTOLOGY AND CYTOLOGY MARKET, BY TEST TYPE

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Microscopy Methods
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Flow Cytometry
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Molecular Genetic Methods
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: HISTOLOGY AND CYTOLOGY MARKET, BY APPLICATION

• 7.1. Overview
  • 7.1.1. Market size and forecast
• 7.2. Drug Discovery and Designing
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by region
  • 7.2.3. Market share analysis by country
• 7.3. Clinical Diagnostics
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by region
  • 7.3.3. Market share analysis by country
• 7.4. Academic Research
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by region
  • 7.4.3. Market share analysis by country

CHAPTER 8: HISTOLOGY AND CYTOLOGY MARKET, BY END USER

• 8.1. Overview
  • 8.1.1. Market size and forecast
• 8.2. Pharma and Biotech Companies
  • 8.2.1. Key market trends, growth factors and opportunities
  • 8.2.2. Market size and forecast, by region
  • 8.2.3. Market share analysis by country
• 8.3. CDMO
  • 8.3.1. Key market trends, growth factors and opportunities
  • 8.3.2. Market size and forecast, by region
  • 8.3.3. Market share analysis by country
• 8.4. Diagnostic Laboratories
  • 8.4.1. Key market trends, growth factors and opportunities
  • 8.4.2. Market size and forecast, by region
  • 8.4.3. Market share analysis by country
• 8.5. Others
  • 8.5.1. Key market trends, growth factors and opportunities
  • 8.5.2. Market size and forecast, by region
  • 8.5.3. Market share analysis by country

CHAPTER 9: HISTOLOGY AND CYTOLOGY MARKET, BY REGION

• 9.1. Overview
  • 9.1.1. Market size and forecast By Region
• 9.2. North America
  • 9.2.1. Key market trends, growth factors and opportunities
  • 9.2.2. Market size and forecast, by Type of Examination
  • 9.2.3. Market size and forecast, by Product
  • 9.2.4. Market size and forecast, by Test Type
  • 9.2.5. Market size and forecast, by Application
  • 9.2.6. Market size and forecast, by End User
  • 9.2.7. Market size and forecast, by country
    • 9.2.7.1. U.S.
    • 9.2.7.1.1. Market size and forecast, by Type of Examination
    • 9.2.7.1.2. Market size and forecast, by Product
    • 9.2.7.1.3. Market size and forecast, by Test Type
    • 9.2.7.1.4. Market size and forecast, by Application
    • 9.2.7.1.5. Market size and forecast, by End User
    • 9.2.7.2. Canada
    • 9.2.7.2.1. Market size and forecast, by Type of Examination
    • 9.2.7.2.2. Market size and forecast, by Product
    • 9.2.7.2.3. Market size and forecast, by Test Type
    • 9.2.7.2.4. Market size and forecast, by Application
    • 9.2.7.2.5. Market size and forecast, by End User
    • 9.2.7.3. Mexico
    • 9.2.7.3.1. Market size and forecast, by Type of Examination
    • 9.2.7.3.2. Market size and forecast, by Product
    • 9.2.7.3.3. Market size and forecast, by Test Type
    • 9.2.7.3.4. Market size and forecast, by Application
    • 9.2.7.3.5. Market size and forecast, by End User
• 9.3. Europe
  • 9.3.1. Key market trends, growth factors and opportunities
  • 9.3.2. Market size and forecast, by Type of Examination
  • 9.3.3. Market size and forecast, by Product
  • 9.3.4. Market size and forecast, by Test Type
  • 9.3.5. Market size and forecast, by Application
  • 9.3.6. Market size and forecast, by End User
  • 9.3.7. Market size and forecast, by country
    • 9.3.7.1. Germany
    • 9.3.7.1.1. Market size and forecast, by Type of Examination
    • 9.3.7.1.2. Market size and forecast, by Product
    • 9.3.7.1.3. Market size and forecast, by Test Type
    • 9.3.7.1.4. Market size and forecast, by Application
    • 9.3.7.1.5. Market size and forecast, by End User
    • 9.3.7.2. France
    • 9.3.7.2.1. Market size and forecast, by Type of Examination
    • 9.3.7.2.2. Market size and forecast, by Product
    • 9.3.7.2.3. Market size and forecast, by Test Type
    • 9.3.7.2.4. Market size and forecast, by Application
    • 9.3.7.2.5. Market size and forecast, by End User
    • 9.3.7.3. UK
    • 9.3.7.3.1. Market size and forecast, by Type of Examination
    • 9.3.7.3.2. Market size and forecast, by Product
    • 9.3.7.3.3. Market size and forecast, by Test Type
    • 9.3.7.3.4. Market size and forecast, by Application
    • 9.3.7.3.5. Market size and forecast, by End User
    • 9.3.7.4. Italy
    • 9.3.7.4.1. Market size and forecast, by Type of Examination
    • 9.3.7.4.2. Market size and forecast, by Product
    • 9.3.7.4.3. Market size and forecast, by Test Type
    • 9.3.7.4.4. Market size and forecast, by Application
    • 9.3.7.4.5. Market size and forecast, by End User
    • 9.3.7.5. Spain
    • 9.3.7.5.1. Market size and forecast, by Type of Examination
    • 9.3.7.5.2. Market size and forecast, by Product
    • 9.3.7.5.3. Market size and forecast, by Test Type
    • 9.3.7.5.4. Market size and forecast, by Application
    • 9.3.7.5.5. Market size and forecast, by End User
    • 9.3.7.6. Rest of Europe
    • 9.3.7.6.1. Market size and forecast, by Type of Examination
    • 9.3.7.6.2. Market size and forecast, by Product
    • 9.3.7.6.3. Market size and forecast, by Test Type
    • 9.3.7.6.4. Market size and forecast, by Application
    • 9.3.7.6.5. Market size and forecast, by End User
• 9.4. Asia-Pacific
  • 9.4.1. Key market trends, growth factors and opportunities
  • 9.4.2. Market size and forecast, by Type of Examination
  • 9.4.3. Market size and forecast, by Product
  • 9.4.4. Market size and forecast, by Test Type
  • 9.4.5. Market size and forecast, by Application
  • 9.4.6. Market size and forecast, by End User
  • 9.4.7. Market size and forecast, by country
    • 9.4.7.1. Japan
    • 9.4.7.1.1. Market size and forecast, by Type of Examination
    • 9.4.7.1.2. Market size and forecast, by Product
    • 9.4.7.1.3. Market size and forecast, by Test Type
    • 9.4.7.1.4. Market size and forecast, by Application
    • 9.4.7.1.5. Market size and forecast, by End User
    • 9.4.7.2. China
    • 9.4.7.2.1. Market size and forecast, by Type of Examination
    • 9.4.7.2.2. Market size and forecast, by Product
    • 9.4.7.2.3. Market size and forecast, by Test Type
    • 9.4.7.2.4. Market size and forecast, by Application
    • 9.4.7.2.5. Market size and forecast, by End User
    • 9.4.7.3. India
    • 9.4.7.3.1. Market size and forecast, by Type of Examination
    • 9.4.7.3.2. Market size and forecast, by Product
    • 9.4.7.3.3. Market size and forecast, by Test Type
    • 9.4.7.3.4. Market size and forecast, by Application
    • 9.4.7.3.5. Market size and forecast, by End User
    • 9.4.7.4. Australia
    • 9.4.7.4.1. Market size and forecast, by Type of Examination
    • 9.4.7.4.2. Market size and forecast, by Product
    • 9.4.7.4.3. Market size and forecast, by Test Type
    • 9.4.7.4.4. Market size and forecast, by Application
    • 9.4.7.4.5. Market size and forecast, by End User
    • 9.4.7.5. South Korea
    • 9.4.7.5.1. Market size and forecast, by Type of Examination
    • 9.4.7.5.2. Market size and forecast, by Product
    • 9.4.7.5.3. Market size and forecast, by Test Type
    • 9.4.7.5.4. Market size and forecast, by Application
    • 9.4.7.5.5. Market size and forecast, by End User
    • 9.4.7.6. Rest of Asia-Pacific
    • 9.4.7.6.1. Market size and forecast, by Type of Examination
    • 9.4.7.6.2. Market size and forecast, by Product
    • 9.4.7.6.3. Market size and forecast, by Test Type
    • 9.4.7.6.4. Market size and forecast, by Application
    • 9.4.7.6.5. Market size and forecast, by End User
• 9.5. Latin America
  • 9.5.1. Key market trends, growth factors and opportunities
  • 9.5.2. Market size and forecast, by Type of Examination
  • 9.5.3. Market size and forecast, by Product
  • 9.5.4. Market size and forecast, by Test Type
  • 9.5.5. Market size and forecast, by Application
  • 9.5.6. Market size and forecast, by End User
  • 9.5.7. Market size and forecast, by country
    • 9.5.7.1. Brazil
    • 9.5.7.1.1. Market size and forecast, by Type of Examination
    • 9.5.7.1.2. Market size and forecast, by Product
    • 9.5.7.1.3. Market size and forecast, by Test Type
    • 9.5.7.1.4. Market size and forecast, by Application
    • 9.5.7.1.5. Market size and forecast, by End User
    • 9.5.7.2. Colombia
    • 9.5.7.2.1. Market size and forecast, by Type of Examination
    • 9.5.7.2.2. Market size and forecast, by Product
    • 9.5.7.2.3. Market size and forecast, by Test Type
    • 9.5.7.2.4. Market size and forecast, by Application
    • 9.5.7.2.5. Market size and forecast, by End User
    • 9.5.7.3. Argentina
    • 9.5.7.3.1. Market size and forecast, by Type of Examination
    • 9.5.7.3.2. Market size and forecast, by Product
    • 9.5.7.3.3. Market size and forecast, by Test Type
    • 9.5.7.3.4. Market size and forecast, by Application
    • 9.5.7.3.5. Market size and forecast, by End User
    • 9.5.7.4. Rest of Latin America
    • 9.5.7.4.1. Market size and forecast, by Type of Examination
    • 9.5.7.4.2. Market size and forecast, by Product
    • 9.5.7.4.3. Market size and forecast, by Test Type
    • 9.5.7.4.4. Market size and forecast, by Application
    • 9.5.7.4.5. Market size and forecast, by End User
• 9.6. Middle East and Africa
  • 9.6.1. Key market trends, growth factors and opportunities
  • 9.6.2. Market size and forecast, by Type of Examination
  • 9.6.3. Market size and forecast, by Product
  • 9.6.4. Market size and forecast, by Test Type
  • 9.6.5. Market size and forecast, by Application
  • 9.6.6. Market size and forecast, by End User
  • 9.6.7. Market size and forecast, by country
    • 9.6.7.1. Gcc
    • 9.6.7.1.1. Market size and forecast, by Type of Examination
    • 9.6.7.1.2. Market size and forecast, by Product
    • 9.6.7.1.3. Market size and forecast, by Test Type
    • 9.6.7.1.4. Market size and forecast, by Application
    • 9.6.7.1.5. Market size and forecast, by End User
    • 9.6.7.2. South Africa
    • 9.6.7.2.1. Market size and forecast, by Type of Examination
    • 9.6.7.2.2. Market size and forecast, by Product
    • 9.6.7.2.3. Market size and forecast, by Test Type
    • 9.6.7.2.4. Market size and forecast, by Application
    • 9.6.7.2.5. Market size and forecast, by End User
    • 9.6.7.3. North Africa
    • 9.6.7.3.1. Market size and forecast, by Type of Examination
    • 9.6.7.3.2. Market size and forecast, by Product
    • 9.6.7.3.3. Market size and forecast, by Test Type
    • 9.6.7.3.4. Market size and forecast, by Application
    • 9.6.7.3.5. Market size and forecast, by End User
    • 9.6.7.4. Rest Of Mea
    • 9.6.7.4.1. Market size and forecast, by Type of Examination
    • 9.6.7.4.2. Market size and forecast, by Product
    • 9.6.7.4.3. Market size and forecast, by Test Type
    • 9.6.7.4.4. Market size and forecast, by Application
    • 9.6.7.4.5. Market size and forecast, by End User

CHAPTER 10: COMPETITIVE LANDSCAPE

• 10.1. Introduction
• 10.2. Top winning strategies
• 10.3. Product mapping of top 10 player
• 10.4. Competitive dashboard
• 10.5. Competitive heatmap
• 10.6. Top player positioning, 2022

CHAPTER 11: COMPANY PROFILES

• 11.1. Hologic, Inc.
  • 11.1.1. Company overview
  • 11.1.2. Key executives
  • 11.1.3. Company snapshot
  • 11.1.4. Operating business segments
  • 11.1.5. Product portfolio
  • 11.1.6. Business performance
• 11.2. F. Hoffmann-La Roche Ltd.
  • 11.2.1. Company overview
  • 11.2.2. Key executives
  • 11.2.3. Company snapshot
  • 11.2.4. Operating business segments
  • 11.2.5. Product portfolio
  • 11.2.6. Business performance
  • 11.2.7. Key strategic moves and developments
• 11.3. Abbott Laboratories
  • 11.3.1. Company overview
  • 11.3.2. Key executives
  • 11.3.3. Company snapshot
  • 11.3.4. Operating business segments
  • 11.3.5. Product portfolio
  • 11.3.6. Business performance
• 11.4. Becton, Dickinson, and Company
  • 11.4.1. Company overview
  • 11.4.2. Key executives
  • 11.4.3. Company snapshot
  • 11.4.4. Operating business segments
  • 11.4.5. Product portfolio
  • 11.4.6. Business performance
  • 11.4.7. Key strategic moves and developments
• 11.5. Danaher Corporation
  • 11.5.1. Company overview
  • 11.5.2. Key executives
  • 11.5.3. Company snapshot
  • 11.5.4. Operating business segments
  • 11.5.5. Product portfolio
  • 11.5.6. Business performance
• 11.6. Merck KGaA
  • 11.6.1. Company overview
  • 11.6.2. Key executives
  • 11.6.3. Company snapshot
  • 11.6.4. Operating business segments
  • 11.6.5. Product portfolio
  • 11.6.6. Business performance
• 11.7. Thermo Fisher Scientific, Inc.
  • 11.7.1. Company overview
  • 11.7.2. Key executives
  • 11.7.3. Company snapshot
  • 11.7.4. Operating business segments
  • 11.7.5. Product portfolio
  • 11.7.6. Business performance
• 11.8. Sysmex Corporation
  • 11.8.1. Company overview
  • 11.8.2. Key executives
  • 11.8.3. Company snapshot
  • 11.8.4. Operating business segments
  • 11.8.5. Product portfolio
  • 11.8.6. Business performance
• 11.9. Trivitron Healthcare Private Limited
  • 11.9.1. Company overview
  • 11.9.2. Key executives
  • 11.9.3. Company snapshot
  • 11.9.4. Operating business segments
  • 11.9.5. Product portfolio
• 11.10. Koninklijke Philips N.V.
  • 11.10.1. Company overview
  • 11.10.2. Key executives
  • 11.10.3. Company snapshot
  • 11.10.4. Operating business segments
  • 11.10.5. Product portfolio
  • 11.10.6. Business performance

관련자료